好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Endpoint Assessment of Disease Burden in Huntington’s Disease (LEAD-HD): A Remote Natural History Study of Huntington’s Disease
Movement Disorders
P2 - Poster Session 2 (11:45 AM-12:45 PM)
16-014

To collect patient-reported data in Huntington’s Disease (HD) and evaluate the ability of various disease-specific Patient-Reported Outcome (PRO) measures to track HD symptoms over time. 

HD clinical trials require outcome measures that are clinically relevant, reliable, and responsive to changes in disease burden. The Huntington’s Disease-Health Index (HD-HI) and the Huntington’s Disease-Patient Report of Problems (HD-PROP) are disease-specific PROs developed to measure how individuals with HD feel and function. LEAD-HD is implementing the HD-HI and the HD-PROP in a longitudinal study to generate performance metrics of these PROs and collect patient-reported natural history data. 

Adults with HD are participating in a remote, 2-year study via the myHDStory research platform. At baseline, participants complete demographic questions, the HD-HI, HD-PROP, HLS19-Q12 health literacy questionnaire, and self-reported Total Functional Capacity (TFC) scale. At 6, 12, 18, and 24 months, participants will complete the HD-HI, HD-PROP, and TFC scales. The primary analysis will examine longitudinal trajectories of PRO scores and explore associations between baseline demographic characteristics and disease progression.

To date, there are 50 participants with 31 providing complete baseline data. Current participants are 74.2% female, range in age from 24-73 years, and have a mean age at diagnosis of 39.5 +/- SD 13.1 years. Mean baseline total HD-HI scores were 20.8 +/- SD 21.2 points (scores range 0-100; higher score = more disease burden). On the HD-PROP, the most serious HD-related problems reported were balance issues, impaired memory, reduced enjoyment reading, difficulty with community interactions, and impaired executive function.

LEAD-HD enables patients to report their experiences with HD via the myHDstory research platform. Future data will determine the ability of the HD-HI and HD-PROP to track changes in HD symptoms over time, which may facilitate future HD clinical trial outcomes and design.

Authors/Disclosures
Jamison Seabury (University of Rochester)
PRESENTER
Jamison Seabury has nothing to disclose.
Lauren Falanga Mrs. Falanga has received personal compensation for serving as an employee of Huntington Study Group.
Karen E. Anderson Ms. Anderson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for teva. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AskBio. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Biogen. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Ms. Anderson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for neurocrine. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medscape. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for atheneum. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GLG. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a scientific advisor with CHDI.
Sandra K. Kostyk, MD, PhD (Prilenia Therapeutics.) Dr. Kostyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WaveLifeScience. Dr. Kostyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Kostyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Kostyk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prilenia Therapeutics. The institution of Dr. Kostyk has received research support from Michael J Fox Foundation. The institution of Dr. Kostyk has received research support from Craig Nielsen Foundation. The institution of Dr. Kostyk has received research support from CHDI Foundaton. The institution of Dr. Kostyk has received research support from UniQure. The institution of Dr. Kostyk has received research support from Voyager Therapeutics. The institution of Dr. Kostyk has received research support from WaveLife Sciences. The institution of Dr. Kostyk has received research support from Vaccinex . The institution of Dr. Kostyk has received research support from Neurocrine Biosciences. The institution of Dr. Kostyk has received research support from Prilenia.
Michael Lentine, MBA Mr. Lentine has received personal compensation for serving as an employee of Huntington Study Group.
Samuel A. Frank, MD, FAAN (Beth Israel Deaconess Medical Center/Harvard Medical School) Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for uniQure. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Frank has received research support from Huntington's Disease Society of America. The institution of Dr. Frank has received research support from Roche/Genentech. The institution of Dr. Frank has received research support from CHDI Foundation. The institution of Dr. Frank has received research support from Huntington Study Group. The institution of Dr. Frank has received research support from Cerevel.
William A. Dalrymple, MD (University of Virginia Health System) Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as a Consultant for REACH. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for M3. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Boxer Capital. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Capvision. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atheneum. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Cencora. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Lumanity. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Huntington Study Group. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Huntington Study Group. The institution of Dr. Dalrymple has received research support from Huntington's Disease Society of America.